What's Happening?
Guided Therapeutics Inc. has reported its financial results for the first quarter of 2026, showing no revenue and a net loss of $1.01 million, or $0.01 per diluted share. This compares to a net loss of $463,000
in the same quarter last year. Despite the financial challenges, the company is making progress in regulatory and commercial areas. It has completed a pivotal U.S. trial and plans to file for FDA premarket approval in Q2 2026. Additionally, the company is expanding its market presence in the U.S., China, and Europe, with confirmed orders in Turkey and Indonesia.
Why It's Important?
The financial results highlight the challenges faced by Guided Therapeutics in generating revenue. However, the company's regulatory progress and market expansion efforts indicate potential future growth. The completion of a pivotal U.S. trial and plans for FDA approval are significant milestones that could enhance the company's market position. The expansion into international markets, despite geopolitical challenges, demonstrates the company's commitment to growth and diversification.
What's Next?
Guided Therapeutics plans to file for FDA premarket approval in Q2 2026, which could open new opportunities in the U.S. market. The company is also targeting potential sales of $1 million over the next 12 months from existing orders and discussions. As the company continues to expand its market presence, it will need to navigate regulatory and geopolitical challenges to achieve its growth objectives.
